Oxford BioMedica/Sanofi Make Headway With FDA On TroVax Cancer Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug makers reaffirm commitment to developing TroVax, a therapeutic vaccine for renal cancer and potentially colorectal cancer.
You may also be interested in...
Bavarian Nordic To Take Prostvac Therapeutic Prostate Cancer Vaccine Into Phase III
Danish firm won license for the therapy, once held by defunct Therion, in CRADA with NCI.
Bavarian Nordic To Take Prostvac Therapeutic Prostate Cancer Vaccine Into Phase III
Danish firm won license for the therapy, once held by defunct Therion, in CRADA with NCI.
Provenge Fails To Meet Interim Study Endpoint, But Dendreon Will Press On
Prostate cancer immunotherapy reduces risk of death by 20 percent compared with placebo, but falls shy of target.